Corcept Therapeutics (CORT)

Apr 23, 2025, 11:30 AM EDT - 4 hours ago

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

Apr 22, 2025, 5:23 PM EDT - 22 hours ago

Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss

Apr 21, 2025, 8:00 AM EDT - 2 days ago

Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

Apr 15, 2025, 4:00 PM EDT - 8 days ago

It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder

Apr 7, 2025, 8:00 AM EDT - 16 days ago

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

Apr 1, 2025, 1:43 PM EDT - 22 days ago

Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release

Apr 1, 2025, 7:15 AM EDT - 22 days ago

Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company

Mar 31, 2025, 3:01 PM EDT - 23 days ago

Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast

Mar 31, 2025, 8:18 AM EDT - 23 days ago

Corcept's ovarian cancer combination drug meets main goal in late-stage study

Mar 31, 2025, 8:00 AM EDT - 23 days ago

Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Mar 12, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman, LLC (CORT) Investors to Inquire about Securities Investigation

Mar 11, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Shareholders to Inquire about Securities Investigation

Mar 10, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Connect

Mar 10, 2025, 8:00 AM EDT - 6 weeks ago

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Mar 9, 2025, 10:00 AM EDT - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Reach Out

Mar 7, 2025, 10:00 AM EST - 6 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Shareholders to Learn More About the Investigation

Mar 6, 2025, 10:00 AM EST - 6 weeks ago

Corcept Therapeutics Incorporated (CORT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Mar 5, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Investors to Connect

Mar 4, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Stockholders to Inquire about Securities Investigation

Mar 4, 2025, 7:03 AM EST - 7 weeks ago

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

GILD PRVA TGTX TKO

Mar 3, 2025, 4:05 PM EST - 7 weeks ago

FDA Files Corcept's New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

Mar 3, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Investors to Learn More About the Investigation

Mar 2, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Stockholders to Learn More About the Investigation

Feb 28, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Investors to Inquire about Securities Investigation

Feb 27, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Investors to Reach Out

Feb 26, 2025, 9:53 PM EST - 7 weeks ago

Corcept Therapeutics, Inc. (CORT) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 7 weeks ago

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

Feb 26, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Reach Out

Feb 25, 2025, 10:30 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Connect

Feb 12, 2025, 4:05 PM EST - 2 months ago

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

Jan 29, 2025, 7:37 AM EST - 3 months ago

Big Money Keeps Buying Corcept

Jan 24, 2025, 11:00 AM EST - 3 months ago

Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm

Jan 22, 2025, 2:03 PM EST - 3 months ago

Corcept Therapeutics Generating Strong Revenue And Profit Growth

Dec 30, 2024, 5:15 PM EST - 4 months ago

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

Dec 16, 2024, 8:00 AM EST - 4 months ago

Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

Dec 12, 2024, 4:05 PM EST - 4 months ago

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes

Dec 11, 2024, 5:27 PM EST - 4 months ago

Corcept Therapeutics' ALS drug fails in mid-stage trial

Dec 11, 2024, 4:05 PM EST - 4 months ago

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

Nov 27, 2024, 8:00 AM EST - 5 months ago

Corcept Therapeutics: A Most Promising And Compelling Biotech

Oct 30, 2024, 9:00 PM EDT - 6 months ago

Corcept Therapeutics Incorporated (CORT) Q3 2024 Earnings Call Transcript